Bionano Genomics Inc. (BNGO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, BNGO scores 30 out of 100 and receives a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars sit where the cash economics are weakest: the cash engine yields negative ROIC and zero FCF yield, meaning the business is not currently converting capital into surplus cash. The institutional and insider pillars are also scored low, indicating limited evidence of smart-money conviction in the source data. The forensic balance sheet score is the strongest pillar yet still sits below midpoint, with a Piotroski F of 4/9 signaling weak financial health indicators. The macro pillar reflects a Beta of 1.0, which by itself implies market-level sensitivity rather than an asymmetric risk profile. Upside drivers would have to come from a sharp change in operating economics, since the current data offers no earnings-based valuation anchor (P/E and EPS are not available in source data). Valuation tradeoffs are therefore difficult to quantify from this dataset. The rating is analytical, not a personalized recommendation.

Bionano Genomics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Laboratory Analytical Instruments. Per the company profile, its market capitalization is $0.0B. Specific product lines, customer segments, and revenue-generation mechanics are not available in source data. The reported gross margin of 46.3% indicates the company retains a portion of revenue after direct costs, per the market data section.

Per the SEC financials, revenue declined across the three reported periods while operating and net losses narrowed from FY 2023 to FY 2025. Operating margin is -60% and net margin is -60% per the market data section, with ROIC at -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, per the Roarable RQD rating. Debt/Equity is 0.5 per the same source, while cash was $3.0M at FY 2025 per the SEC financials.

Per the recent news wire, catalysts include a TradingView estimates report, a StreetInsider report on a $400M mixed shelf filing, and a Stock Titan report stating the company is needing capital in the very near term and has amended its offering plan. A TradingView report references a Q3'26 revenue estimate of 8.44M USD, and a Pluang report states the company will report Q3 2026 results and host a webcast on Nov 10. All news items are flagged YELLOW. Risk watch items include the shelf registration and offering amendment, which relate to potential equity dilution, and the stated near-term capital need. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The one investor-relevant ripple the sources do surface is financing-related: the shelf filing and offering amendment alongside the near-term capital need point to the possibility that capital-raising activity could affect the share count, a mechanism worth monitoring around the Nov 10 results webcast.

• What is the company's cash runway given the stated near-term capital need, and how does it compare to the $3.0M FY 2025 cash balance?
• What are the terms and size of the offering amendment tied to the $400M mixed shelf, and how much of it is expected to be used?
• What drove the revenue decline from $36.1M to $28.5M across the reported periods?
• Which specific product lines and customers generate the reported revenue?
• What do the Q3 2026 results on Nov 10 show relative to the cited 8.44M USD revenue estimate?